Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors

AIDS

Volumn 13, Issue 10, 1999, Pages

  Behrens, Georg ^a   Dejam, Andre ^a   Schmidt, Hartmut ^a   Balks, Hans Joachim ^a   Brabant, Georg ^a   Körner, Thorsten ^a   Stoll, Matthias ^a   Schmidt, Reinhold E ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Diabetes; Hyperlipidemia; Impaired glucose tolerance; Lipid metabolism; Metabolic abnormalities; Protease inhibitor

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; C PEPTIDE; CARDIOLIPIN ANTIBODY; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HOMOCYSTEINE; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PROINSULIN; PROTEINASE INHIBITOR; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ANTI-HIV AGENTS; BLOOD GLUCOSE; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; FEMALE; GLUCOSE INTOLERANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERINSULINISM; HYPERLIPIDEMIAS; INSULIN; ISLETS OF LANGERHANS; LIPID METABOLISM; LIPOPROTEINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032797624     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907090-00001     Document Type: Article

References (31)

1. 1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 352:1725-1730.
2. 2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbiditiy and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
3. 3. Race FM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998, 351:252-255.
4. 4. Behrens G, Knuth C, Schedel I, Mendila M, Schmidt RE. Highly active antiretroviral therapy, Lancet 1998, 351:1057-1058.
5. 5. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
6. 6. Walli R, Herford O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1 infected patients. AIDS 1998, 12:F167-F173.
7. 7. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV infection, Lancet 1998, 351:867-870.
8. 8. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Fallon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
9. 9. Dube MP, Johnson DI, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycemia. Lancet 1997, 350:713-714.
10. 10. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors, Lancet 1998, 351:1328.
11. 11. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with the use of HIV protease inhibitors. Lancet 1998, 351:1958.
12. 12. SoRelle R. Vascular and lipid syndromes in selected HIV-infected patients. Circulation 1998, 9:829-830.
13. 13. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
14. 14. Henry K, Melroe H, Huebsch J, Hermundson J, Simpson J. Atorvastatin and gemfibrazol for protease-inhibitor-related lipid abnormalities. Lancet 1998, 352:1031-1032.
15. 15. Thai MM. A mathematic model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 1994, 17:152-154.
16. 16. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 7:1183-1197.
17. 17. Martinez E, Lozano L, Conget I, Casamitjana R, Gatell JM. Reversion of lipodystrophy after switching HIV-1 protease inhibitors to nevirapine. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 670].
18. 18. Ruiz L, Bonjoch A, Paredes R, et al. A multi-center, randomized, open-labeled, comparative trail of the clinical benefit of switching the protease inhibitor (PI) by Nevirapine (NVP) in HAART-experienced patients suffering lipodystrophy (LD). Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract LB14].
19. 19. Williams DR, Byrne C, Clark PM, et al. Raised proinsulin concentration as early indicator of β cell dysfunction. BMJ 1991, 303:93-96.
20. 20. Roder ME, Porte D, Schwartz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired β cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Endocrinol Metab 1998, 83:604-608.
21. 21. Nijpels G, Popp-Snyders C, Kostense PJ, Bouler LM, Heine RJ. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologica 1996, 39:113-118.
22. 22. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennet PH. A two-step model for the development of non-insulin-dependent diabetes. Am J Med 1991, 90:229-235.
23. 23. Heine RJ, Nijpels G, Mooy JM. New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors. Diabetes Med 1996, 13:512-514.
24. 24. Mykkänen L, Haffner SM, Kuusisto J, Pyörälä K, Laakso M. Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Diabetologica 1995, 38:1176-1182.
25. 25. Hommes MJT, Romijn JA, Endert E, Schattenkerk JKME, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991, 40:651-656.
26. 26. Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK. Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetes. Metabolism 1988, 37:338-345.
27. 27. Jarrett RJ. The cardiovascular risk associated with impaired glucose tolerance. Diabetic Med 1996, 13:S15-S19.
28. 28. Båvenholm P, Karpe F, Proudler A, Tornvall P, Crook D, Hamsten A. Association of insulin and insulin propeptides with atherogenic lipoprotein phenotypes. Metabolism 1995, 44:1481-1488.
29. 29. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
30. 30. Lipshultz SE. Dilated cardiomyopathy in HIV-infected patients. N Engl J Med 1998, 339:1153-1155.
31. 31. Katlama C, Murphy R, Johnson V, et al. The Atlantic Study. A randomised open-label study comparing two protease inhibitors (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 647].